profile image

Steve Morgan

Professor of health policy at the University of British Columbia and Founder of Pharmacare 2020; Expert advisor with EvidenceNetwork.ca

Steve Morgan is an expert advisor with EvidenceNetwork.ca and Associate Professor and Associate Director of the Centre for Health Services and Policy Research at the University of British Columbia.
Cecilie_Arcurs via Getty Images

4 Reasons Canada Needs Universal Pharmacare Now

Several national commissions on Canada's health care system have recommended adding prescription drugs to our publicly funded universal medicare system. No federal government has ever acted on those recommendations. Not yet, anyhow. By creating 'pharmacare-junior,' Premier Wynne and Minister Hoskins are in essence calling on the federal government to help finish the job and create a pharmacare program for all Canadians of all ages.
05/08/2017 05:03 EDT
Shutterstock / Pruser

Why We Need to Cover Medication for Children

The glaring gaps in drug coverage for Canadian children are made stranger by the economic dimensions of the issue. Children's health care represents a drop in the ocean of health care budgets -- extending universal drug coverage to children would constitute a small fraction of total pharmaceutical spending.
10/17/2015 08:45 EDT
Getty

Canadians Should Not Shoulder Prescription Drug Costs

Cities have to spend this money, taken from local taxpayers, because Canada's medicare system is the only universal, public health care system among developed countries that does not include universal coverage of prescription drugs. It is not wrong for cities to care for their employees. But leaving these costs to the cities makes about as much sense as requiring every homeowner to maintain the roads and infrastructure surrounding their property. Here's why.
05/22/2015 08:10 EDT
Geri Lavrov

Universal Canadian Drug Coverage Is Good for Business

Businesses care about the health and well-being of the Canadian workforce. Employees that can afford the medicines as and when prescribed will be healthier, happier, and more productive. In this election year, it is time for Canada's business leaders to call for universal, public pharmacare.
04/23/2015 12:59 EDT
Getty Images

New Brunswick's Opportunity to Reduce Pharmaceutical Drug Prices

The Liberal government of New Brunswick appears to be stepping back from the brink of mandatory prescription drug insurance. And so they should. The drug plan chosen by the Conservatives was designed on a false premise: that the private sector can better manage things than government can. In many sectors, that might be true. But not in health care.
12/19/2014 06:12 EST
Getty

The New Brunswick Drug Plan With Great Potential

The Alward government has just adopted pharmacare reforms that have great potential to do good -- and great potential to cost New Brunswickers far more than it should. The New Brunswick drug plan bears little resemblance to catastrophic drug plans in other provinces. That is a good thing.
01/07/2014 05:09 EST
Shutterstock / Tish1

The Incoming Rise of Prescription Drug Spending

The slowdown in total spending on prescriptions in Canada masks dramatic changes in the pharmaceutical sector. Beneath the calm surface lies a rapid decline in spending on widely used medicines to treat relatively common conditions, and even more dramatic increases in spending on medicines used by relatively few people who suffer from serious conditions.
12/18/2013 12:31 EST
Shutterstock

How Canada's Pharmacare System Is Costing Us Billions

Our fragmented system of prescription drug financing is the root cause of our troubles. Not recognizing that our pharmacare system (or lack thereof) is designed to fail is costing us billions of dollars every year while many Canadians go without access to the medicines they need.
04/02/2013 04:55 EDT
Alamy

Canada's Drug Patent Process Needs Rx

The current rush to approve medicines while manufacturers' "patent clocks" are ticking means that some medicines make it to market that later must be recalled because of harms they cause to patients -- harms that could be detected with more thorough pre-market evaluation.
11/20/2012 02:12 EST